Younossi ZM, et al. - The effect of treating hepatitis C virus (HCV) in patients with no or minimal fibrosis (Metavir stage F0–F1) on patient-reported outcomes (PROs) was assessed. They collected PROs of 1,548 HCV-infected patients with F0–F1 from 16 clinical trials before, during, and after treatment. Patients were treated with interferon (IFN) + sofosbuvir (SOF) + ribavirin (RBV) or SOF + RBV with or without ledipasvir or IFN- and RBV-free regimens with SOF + ledipasvir or SOF + velpatasvir or SOF + velpatasvir + voxilaprevir. Outcomes revealed that treatment with IFN- and RBV-free regimens result in on-treatment and post-sustained virologic response PRO improvements among these patients.